Afizagabar

DB21439InvestigationalSmall molecule

Afizagabar is a small molecule drug. Afizagabar is under investigation in clinical trial NCT02877615 (Efficacy and Safety Trial With S 44819 After Recent Ischemic Cerebral Event). Afizagabar has a monoisotopic...

Mechanism: Pharmacologically active on Gamma-aminobutyric acid receptor subunit alpha-5
Curator reviewed
Formula / weight: C₁₉H₁₂FN₃O₂S · 365.38 g/mol (avg)
Code names: S-44819

Resolves to

Compound

UNIIZD6M94A8IHCAS1398496-82-6ChEMBLCHEMBL3652871

Structure

InChIKeyWNUWGRVHGICCLS-UHFFFAOYSA-NSMILESCC1=NN=C(C2=CC3=C(F)C=CC=C3S2)C2=C(C1)C=C1NC(=O)OC1=C2

Targets

P31644GABRA5

What you can answer from here — as of August 31, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with Afizagabar, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account